Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII

Haemophilia

Volumn 17, Issue 5, 2011, Pages

  El Ekiaby, M ^a   Goubran, H A ^b,c   Radosevich, M ^d   Abd Allah, A ^a   El Ekiaby, A ^a   Burnouf, T ^d,e  

^a Shabrawishi Hospital Blood Bank   (Egypt)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Faculty of Medicine   (Egypt)

^d HUMAN PROTEIN PROCESS SCIENCES   (France)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cryoprecipitate; Factor VIII; Half life; Minipool; Recovery; Solvent detergent

Indexed keywords

AGGLUTININ; BLOOD CLOTTING FACTOR 8 CRYOPRECIPITATE; DRUG SOLVENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RISTOCETIN;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONVALESCENCE; CRYOPRECIPITATE; DRUG CLEARANCE; DRUG FEVER; DRUG HALF LIFE; DRUG TOLERANCE; DYSPNEA; HEMOPHILIA A; HOSPITALIZATION; HUMAN; HYPOTENSION; LUNG EDEMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SHOCK; TREATMENT RESPONSE;

ADOLESCENT; ADULT; BLOOD PRESERVATION; CHILD; FACTOR VIII; FIBRINOGEN; HALF-LIFE; HEMOPHILIA A; HUMANS; METABOLIC CLEARANCE RATE; SOLVENTS; YOUNG ADULT;

EID: 80052023709     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02511.x     Document Type: Article

References (23)

1. Srivastava A. Factor replacement therapy in haemophilia - are there models for developing countries? Haemophilia 2003; 9: 391-6.
2. Srivastava A. Factor replacement for haemophilia - should cryoprecipitate be used? Haemophilia 1999; 5: 301-5.
3. Farrugia A, Giangrande P. Choice of replacement therapy for hemophilia-cryoprecipitate issues: a rebuttal. J Thromb Haemost 2004; 2: 1022-3.
4. Kasper CK. Products for clotting factor replacement in developing countries. Semin Thromb Hemost 2005; 31: 507-12.
5. Ness PM, Perkins HA. Cryoprecipitate as a reliable source of fibrinogen replacement. JAMA 1979; 241: 1690-1.
6. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007; 92: 846-9.
7. Marshall S. Commercial fibrinogen, autogenous plasma, whole blood and cryoprecipitate for coagulum pyelolithotomy: a comparative study. J Urol 1978; 119: 310-1.
8. Anonymous. Blood supply and demand. Lancet 2005; 365: 2151.
9. Evatt B, Austin H, Leon G, Ruiz-Saez A, de Bosch N. Hemophilia treatment. Predicting the long-term risk of HIV exposure by cryoprecipitate. Haemophilia 2000; 6(Suppl. 1): 128-32.
10. Burnouf T, Caron C, Radosevich M, Goubran HA, Goudemand J, El-Ekiaby M. Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems. Haemophilia 2008; 14: 956-62.
11. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-40.
12. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. Transfusion 2006; 46: 2100-8.
13. Burnouf T, Goubran H, Radosevich M, El-Ekiaby M. Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries. ISBT Science Series 2007; 2: 121-8.
14. Shargel L, Wu-Pong S, Yu ABC. Mathematical Fundamentals in Pharmacokinetics. Boston: McGraw Hill, 2005.
15. Dichtelmuller HO, Biesert L, Fabbrizzi F et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009; 49: 1931-43.
16. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39: 1160-8.
17. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000; 14: 94-110.
18. Klein HG. Pathogen inactivation technology: cleansing the blood supply. J Intern Med 2005; 257: 224-37.
19. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sang 2006; 91: 56-62.
20. El-Ekiaby M, Sayed MA, Caron C et al. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med 2010; 20: 48-61.
21. Sousa NC, Anicchino-Bizzacchi JM, Locatelli MF, Castro V, Barjas-Castro ML. The relationship between ABO groups and subgroups, factor VIII and von Willebrand factor. Haematologica 2007; 92: 236-9.
22. Jeanne M, Piquet Y, Ivanovic Z, Vezon G, Salmi LR. Variations of factor VIII:C plasma levels with respect to the blood group ABO. Transfus Med 2004; 14: 187-8.
23. Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant factor VIII Study Group. N Engl J Med 1990; 323: 1800-5.